Photo from Joshua Bauml/X
Sep 27, 2024, 15:04
Joshua Bauml: The U.S. FDA approved our targeted therapy in combination with for NSCLC with specific EGFR mutations
Joshua Bauml, Vice President, Lung Cancer Disease Area Stronghold (DAS) Leader, shared a post on X:
“The U.S. FDA approved our targeted therapy in combination with chemotherapy for patients with previously treated NSCLC with specific EGFR mutations.
This milestone marks J&J Innovative Medicine’s third new indication in six months for this targeted therapy.”
Source: Joshua Bauml/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19